Biogen - International Biopharmaceutical Industry

news

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s disease drug. Onc...

9 May 2022 news Alzheimer | Biogen

Continue Reading →

news

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is n...

9 May 2022 news Aduhelm | Alzheimer

Continue Reading →

news

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer's disease drug in Europe, marking the latest setback in the company's efforts to ramp up ...

25 April 2022 news Aduhelm | Alzheimer

Continue Reading →

news

Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug

Medicare will not pay for Biogen's new Alzheimer's medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a decis...

11 April 2022 news Alzheimer | Biogen

Continue Reading →

news

Biogen, struggling to sell Alzheimer’s drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes as the Cambridge, Ma...

4 March 2022 news Alzheimer | Biogen

Continue Reading →

news

Sage claims new data show depression drug works, but doubts remain

Dive Brief: An experimental, fast-acting depression drug from Sage Therapeutics and partner Biogen met its main goals in a closely watched Phase 3 study that is me...

18 February 2022 news Biogen | depression

Continue Reading →

news

Al Sandrock, former top Biogen scientist, to join drug discovery startup’s board

Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company's Alzheimer's drug Aduhelm, is joining the board of directors at Verge Ge...

10 February 2022 news Al Sandrock | Alzheimer

Continue Reading →

news

Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts

Biogen recorded $1 million in revenue from its new treatment for Alzheimer's disease in the last quarter of 2021, offering the latest evidence that the drug, which ca...

6 February 2022 news Alzheimer | Biogen

Continue Reading →

news

Medicare proposes to limit coverage of Biogen Alzheimer’s drug

Medicare will restrict coverage of Biogen's controversial Alzheimer's treatment only to patients who take part in a rigorous clinical trial, the federal government an...

14 January 2022 news Alzheimer | Biogen

Continue Reading →

news

Biogen reserves four years for trial meant to confirm its Alzheimer’s drug works

A crucial study evaluating Biogen's approved drug for Alzheimer's disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as expected, ...

16 December 2021 news Aduhelm | Alzheimer

Continue Reading →